Program
buntanetap
Also written as “buntanetap/posiphen”, “Posiphen” and “Buntanetap/Posiphen”.
Its studies are mostly in Alzheimer Disease · Parkinson Disease, led by Annovis Bio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Annovis Bio | 73 open or running | phase 3since Apr 19, 2022 | Sep 29, 2016 | Dec 2027phase 3 · NCT06709014 |
Also a collaborator on its studies: prevail-infoworks, propharma-group, tfs-trial-form-support and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2016First study: phase 2 study in Alzheimer DiseaseFirst studyNCT02925650 · 18 enrolled · United States
- Aug 11, 2020Phase 2 study in Alzheimer DiseaseNCT04524351 · 75 enrolled · United States
- Apr 19, 2022Phase 3 study in Parkinson DiseaseNCT05357989 · 523 enrolled · United States, Germany, Hungary and more
- Jan 6, 2023Phase 3 study in Alzheimer DiseaseNCT05686044 · 351 enrolled · United States
- Nov 26, 2024Phase 3 study in Alzheimer DiseaseNCT06709014 · 760 enrolled · United States
- Nov 26, 2025Phase 3 study in Parkinson DiseaseNCT07284784 · 500 planned · United States
- Jul 31, 2026Phase 3 study in Alzheimer DiseaseNCT07757204 · 400 planned · United States
Ahead
- Dec 2027Primary completion: phase 3 study in Alzheimer DiseaseNCT06709014
- Sep 2029Primary completion: phase 3 study in Parkinson DiseaseNCT07284784
- Feb 21, 2030Primary completion: phase 3 study in Alzheimer DiseaseNCT07757204
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07757204Alzheimer Disease · United States | 3 | Not yet recruiting | Feb 21, 2030 | 400 |
| NCT07284784Parkinson Disease · United States | 3 | Recruiting | Sep 2029 | 500 |
| NCT06709014Alzheimer Disease · United States | 3 | Active, not recruiting | Dec 2027 | 760 |
| NCT05686044Alzheimer Disease · United States | 3 | Completed | Feb 13, 2024 | 351 |
| NCT05357989Parkinson Disease · United States, Germany, Hungary and more | 3 | Completed | Dec 4, 2023 | 523 |
| NCT04524351Alzheimer Disease · United States | 2 | Completed | Aug 16, 2021 | 75 |
| NCT02925650Alzheimer Disease · United States | 2 | Completed | Dec 10, 2021 | 18 |
How it is read
Names in the registry
- “buntanetap/posiphen”, 4 entries
- “Posiphen”, 2 entries
- “Buntanetap/Posiphen”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 5 studies
- Parkinson Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.